PTP4A3 and myeloid neoplasm: Challenges for the future are to determine the dose-effect of PTP4A3 expression in myeloid development and to extend the screens to additional myeloid neoplasms, e.g., myelodysplasia, therapy-related AML, AML secondary to bone marrow failure and myeloproliferative disorders.